Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Greasley

Showing results (21-30 of 85) with videos related to

Pageof 9
Sort By:
Clinical Science (London, England : 1979)|June 5, 2024
Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?Phil Ambery, Peter J Greasley, Robert I Menzies, et al.
Drug Discovery Today|November 7, 2012
Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG caseThierry Kogej, Niklas Blomberg, Peter J Greasley, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2009
Novel thioamide derivatives as neutral CB1 receptor antagonistsJonas Boström, Roine I Olsson, Joakim Tholander, et al.
FEBS Letters|December 29, 2004
Identification and characterisation of a novel splice variant of the human CB1 receptorErik Ryberg, Huy Khang Vu, Niklas Larsson, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|April 21, 2011
N-arachidonoyl-L-serine is neuroprotective after traumatic brain injury by reducing apoptosisAyelet Cohen-Yeshurun, Victoria Trembovler, Alexander Alexandrovich, et al.
BMC Nephrology|August 31, 2025
Kidney transcriptomics signature of prospective rapid diabetic kidney disease progressionDianne Acoba, Anna Levin, Anna Witasp, et al.
Kidney International Reports|October 26, 2020
Impact of CKD Progression on Cardiovascular Disease Risk in a Contemporary UK Cohort of Individuals With DiabetesClaudia S Cabrera, Alison S Lee, Marita Olsson, et al.
Diabetes, Obesity & Metabolism|August 14, 2019
Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetesClaire C J Dekkers, C David Sjöström, Peter J Greasley, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|May 13, 2017
A common NHE3 single-nucleotide polymorphism has normal function and sensitivity to regulatory ligandsJianyi Yin, Chung-Ming Tse, Boyoung Cha, et al.
Diabetes, Obesity & Metabolism|May 21, 2025
Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non-diabetic chronic kidney diseaseVictor Wasehuus, J David Smeijer, Phil Ambery, et al.
Pageof 9

Showing results (21-30 of 85) with videos related to

Sort By:
Pageof 9
Clinical Science (London, England : 1979)|June 5, 2024
Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?Phil Ambery, Peter J Greasley, Robert I Menzies, et al.
Drug Discovery Today|November 7, 2012
Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG caseThierry Kogej, Niklas Blomberg, Peter J Greasley, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2009
Novel thioamide derivatives as neutral CB1 receptor antagonistsJonas Boström, Roine I Olsson, Joakim Tholander, et al.
FEBS Letters|December 29, 2004
Identification and characterisation of a novel splice variant of the human CB1 receptorErik Ryberg, Huy Khang Vu, Niklas Larsson, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|April 21, 2011
N-arachidonoyl-L-serine is neuroprotective after traumatic brain injury by reducing apoptosisAyelet Cohen-Yeshurun, Victoria Trembovler, Alexander Alexandrovich, et al.
BMC Nephrology|August 31, 2025
Kidney transcriptomics signature of prospective rapid diabetic kidney disease progressionDianne Acoba, Anna Levin, Anna Witasp, et al.
Kidney International Reports|October 26, 2020
Impact of CKD Progression on Cardiovascular Disease Risk in a Contemporary UK Cohort of Individuals With DiabetesClaudia S Cabrera, Alison S Lee, Marita Olsson, et al.
Diabetes, Obesity & Metabolism|August 14, 2019
Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetesClaire C J Dekkers, C David Sjöström, Peter J Greasley, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|May 13, 2017
A common NHE3 single-nucleotide polymorphism has normal function and sensitivity to regulatory ligandsJianyi Yin, Chung-Ming Tse, Boyoung Cha, et al.
Diabetes, Obesity & Metabolism|May 21, 2025
Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non-diabetic chronic kidney diseaseVictor Wasehuus, J David Smeijer, Phil Ambery, et al.
Pageof 9